¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"sclerosing basal cell carcinoma"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® thyroid carcinoma ÇÑ±Û °©»ó»ù¾ÏÁ¾
¼³¸í   
  °©»ó»ù¿¡ »ý±ä »óÇǼ¼Æ÷·Î ÀÌ·ç¾îÁø ¾Ç¼ºÁ¾¾ç¹°. º´¸®Á¶Á÷ÇÐÀûÀΠÇüÅ¿¡ µû¶ó À¯µÎ»ó, ¼ÒÆ÷»ó, ¿ªÇü¾ÏÁ¾ ¹× ¼öÁú¾ÏÁ¾, ¸²ÇÁÁ¾ µîÀ¸·Î ³ª´­ ¼ö ÀÖ´Ù. ´Ù¾çÇÑ ¿øÀÎÀÌ ÀÖÀ¸³ª, ÀϺο¡¼­´Â ¹æ»ç¼±Æø·Î¿¡ ÀÇÇØ ¹ß»ýÇÑ´Ù. Ä¡·á´Â ¼ö¼ú, ¹æ»ç¼º ¿Á¼Ò, T4 ¾ïÁ¦¿ä¹ý µîÀÌ »ç¿ëµÈ´Ù.
¿µ¹® bronchogenic carcinoma ÇÑ±Û ±â°üÁö¿ø¼º ¾ÏÁ¾
¼³¸í   
  ÆóÀÇ ±â°üÁö ¼¼Æ÷¿¡¼­ ±â¿øÇϴ Á¾¾ç. Æó¾ÏÀÇ Á¾·ù¿¡¼­ °¡Àå ÈçÇÑ ÇüÅÂ(90%ÀÌ»ó)ÀÌ´Ù. Çö¹Ì°æÀû ¼Ò°ß¿¡ µû¶ó »ù¾ÏÁ¾, Å«¼¼Æ÷¾ÏÁ¾, ¼Ò¼¼Æ÷(ÀÛÀº¼¼Æ÷) ¾ÏÁ¾ÀÇ 4°¡Áö·Î ³ª´«´Ù. ÀÌÁß¿¡¼­ ÆíÆò¼¼Æ÷¾ÏÁ¾ÀÌ °¡Àå ÈçÇÑ ÇüÅÂÀÌ´Ù. ÀÓ»óÀûÀ¸·Î´Â ºñ¼Ò¼¼Æ÷Æó¾Ï(non-small cell lung cancer)¿Í ¼Ò¼¼Æ÷Æó¾Ï(small cell lung cancer)·Î ±¸ºÐÀ» Çϴµ¥, ºñ¼Ò¼¼Æ÷Æó¾ÏÀÇ °æ¿ì Á¾¾ç¼¼Æ÷ÀÇ ¼ºÀåÀÌ ´À¸®°í ¼ö¼úÀû Á¦°Å°¡ Ä¡·áÀÇ ±âº»ÀÌ µÇ°í ¿¹Èĵµ ÁÁÀº ¹Ý¸é, ¼Ò¼¼Æ÷Æó¾ÏÀÇ °æ¿ì¿¡´Â ¾Ï¼¼Æ÷ÀÇ ¼ºÀåÀÌ ¸Å¿ì ºü¸£°í Ä¡·áµµ ¹æ»ç¼±Ä¡·á¸¦ ±âº»À¸·Î Çϸ砿¹Èĵµ ºñ¼Ò¼¼Æ÷Æó¾Ï¿¡ ºñÇØ¼­ ÁÁÁö°¡ ¸øÇÏ´Ù.
¿µ¹® embryonal carcinoma ÇÑ±Û ¹è¾Æ¾ÏÁ¾
¼³¸í   
  »ý½Ä¼¼Æ÷¿¡¼­ »ý±â´Â ¾ÏÁ¾ÀÇ Çϳª·Î ´ëºÎºÐ °íȯ¿¡¼­ ¹ß»ýÇÑ´Ù. µå¹°°Ô´Â Á¾°Ýµ¿¿¡¼­µµ ¹ß»ýÇÑ´Ù. 40~50´ëÀÇ ³²¼º¿¡°Ô ¸¹À¸³ª, À̺¸´Ù ³·Àº ¿¬·ÉÃþ¿¡¼­µµ ³ªÅ¸³­´Ù. À°¾ÈÀûÀ¸·Î´Â È¸¹é»öÀÇ ºÐ¿±À» º¸À̴ µ¢¾î¸®¸¦ Çü¼ºÇϸç, °íȯ ¾Ç¼º Á¾¾ç Áß ¿¹Èİ¡ ÁÁÀº ÆíÀÌ´Ù. Ä¡·áÀÇ ¿øÄ¢Àº °¡±ÞÀû ½Å¼ÓÇϰԠ¿ø¹ß¼Ò¸¦ ÀýÁ¦ÇÏ°í ¿¹»óµÇ´Â ÀüÀ̺´ÅÍ¿¡ ´ëÇÏ¿© ¹æ»ç¼± Á¶»ç¿ä¹ýÀ» ÇàÇØ¾ß ÇÑ´Ù. Å»ý¾ÏÁ¾ ¹æ»ç¼±¿ä¹ý¿¡ ´ëÇÏ¿© ¸Å¿ì °¨¼ö¼ºÀÌ ³ô±â ¶§¹®¿¡ º´±â°¡ ÃʱâÀ̸é 90% ÀÌ»óÀÇ Ä¡·á°¡ ±â´ëµÈ´Ù. ±×¸®°í È­Çпä¹ýÁ¦¿¡ ÀÇÇØ ±× Ä¡·á¼º°ú°¡ »ó½ÂÇϰí ÀÖ´Ù.
¿µ¹® carcinoma in situ ÇÑ±Û »óÇdz»¾ÏÁ¾
¼³¸í   
  ½ÅüÀÇ ³»ºÎ³ª ¿ÜºÎ¸¦ ½×°í Àִ Á¶Á÷À» »óÇǶó°í ÇÑ´Ù. ÀÌ »óÇÇÀÇ ¾Æ·¡¿¡´Â ´ë°³ »óÇǸ¦ ÁöÁöÇϰí Àִ Á¶Á÷ÀÇ À§¿¡ Á¸ÀçÇÑ´Ù. ±×¸®°í ÀÌ ÁöÁöÁ¶Á÷°ú »óÇÇ »çÀÌ¿¡´Â ±âÀú¸·À̶ó´Â ¸·ÀÌ À־ »óÇǿ͠ÁöÁöÁ¶Á÷À» ±¸ºÐÇØ ÁØ´Ù. ¾ÏÁ¾(carcinoma)¶õ »óÇÇÀÇ ¼¼Æ÷°¡ ¾Ç¼º º¯È­¸¦ ÇÏ¿© »ý±â´Â ¾ÏÀ» ¸»ÇÑ´Ù. Á¦ÀÚ¸®¾ÏÁ¾À̶õ ¾ÏÁ¾ÀÇ ÇÑ Á¾·ù·Î ¾ÏÁ¾ÀÌ ±âÀú¸·À» ¹þ¾î³ªÁö ¸øÇÏ°í »óÇdz» Áï, Á¦ÀÚ¸®¿¡ ¸Ó¹°·¯ Àִ °æ¿ì¸¦ ¸»ÇÑ´Ù.
¿µ¹® carcinoma ÇÑ±Û ¾ÏÁ¾
¼³¸í   
  ¾ÏÁ¾À̶õ »óÇǼ¼Æ÷(-½ÅüÀÇ ³»ºÎ³ª ¿ÜºÎ¸¦ ½×°í Àִ Á¶Á÷À» »óÇǶó°í Çϰí, »óÇǸ¦ ÀÌ·ç°í Àִ ¼¼Æ÷¸¦ »óÇǼ¼Æ÷¶ó°í ÇÑ´Ù)ÀÇ °úµµÇÑ Áõ½Ä¿¡ÀÇÇÑ ¾Ç¼ºÁ¾¾çÀ» À̸£´Â ¸»ÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • non-small cell carcinoma
    ºñ¼Ò¼¼Æ÷¾ÏÁ¾
  • oat cell carcinoma
    ±Í¸®¼¼Æ÷¾ÏÁ¾
  • renal cell carcinoma
    ÄáÆÏ¼¼Æ÷¾ÏÁ¾, ½ÅÀå¼¼Æ÷¾ÏÁ¾
  • spindle cell carcinoma
    ¹æÃß¼¼Æ÷¾ÏÁ¾
  • squamous cell carcinoma
    ÆíÆò¼¼Æ÷¾ÏÁ¾
  • squamous cell in situ carcinoma
    ÆíÆò¼¼Æ÷Á¦ÀÚ¸®¾ÏÁ¾
  • signet ring cell carcinoma
    ¹ÝÁö¼¼Æ÷¾ÏÁ¾
  • small cell carcinoma
    ¼Ò¼¼Æ÷¾ÏÁ¾
  • subacute sclerosing panencephalitis
    ¾Æ±Þ¼º°æÈ­¹ü³ú¿°
  • sclerosing
    °æÈ­-
  • sclerosing adenosis
    °æÈ­»ùÁõ, °æÈ­¼±Áõ
  • sclerosing agent
    °æÈ­Á¦
  • sclerosing angioma
    °æÈ­Ç÷°üÁ¾
  • sclerosing cholangitis
    °æÈ­¾µ°³°ü¿°, °æÈ­´ã°ü¿°
  • sclerosing epithelial hamartoma
    °æÈ­Ç¥Çǰú¿ÀÁ¾
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • basal layer
    ¹Ù´ÚÃþ
  • basal lamina
    Ä¡¹ÐÆÇ, ¹Ù´ÚÆÇ
  • basal nuclei
    ¹Ù´ÚÇÙ
  • basal plate
    ¹Ù´ÚÆÇ, ±âÀúÆÇ
  • basal metabolic rate
    ±âÃÊ´ë»çÀ²
  • basal state
    ±âÃÊ»óÅÂ
  • basal body temperature
    ±âÃÊü¿Â
  • carcinoma
    ¾ÏÁ¾
  • carcinoma in situ
    »óÇdz»¾ÏÁ¾
  • anaplastic carcinoma
    ¿ªÇü¼º¾ÏÁ¾
  • follicular carcinoma
    °©»ó»ù¼ÒÆ÷¾ÏÁ¾, ¼ÒÆ÷¾ÏÁ¾
  • invasive carcinoma
    ħ½À¾ÏÁ¾
  • medullary carcinoma
    ¼ÓÁú¾ÏÁ¾, ¼öÁú¾ÏÁ¾
  • neuroendocrine carcinoma
    ½Å°æ³»ºÐºñ¾ÏÁ¾
  • occult breast carcinoma
    ÀáÀçÀ¯¹æ¾ÏÁ¾
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • signet ring cell carcinoma
    ¹ÝÁö¼¼Æ÷¾ÏÁ¾
  • small cell carcinoma
    ¼Ò¼¼Æ÷¾ÏÁ¾
  • spindle cell carcinoma
    ¹æÃß¼¼Æ÷¾ÏÁ¾
  • squamous cell carcinoma
    ÆíÆò¼¼Æ÷¾ÏÁ¾
  • transitional cell carcinoma
    ÀÌÇ༼Æ÷¾ÏÁ¾
  • sclerosing adenitis
    °æÈ­»ù¿°
  • sclerosing adenosis
    °æÈ­»ùÁõ
  • sclerosing agent
    °æÈ­Á¦
  • sclerosing angioma
    °æÈ­Ç÷°üÁ¾
  • sclerosing cholangitis
    °æÈ­¾µ°³°ü¿°
  • subacute sclerosing encephalitis
    ¾Æ±Þ¼º°æÈ­³ú¿°
  • sclerosing fibrosis
    °æÈ­¼¶À¯Áõ
  • sclerosing gastritis
    °æÈ­À§¿°
  • sclerosing hemangioma
    °æÈ­Ç÷°üÁ¾
  • sclerosing histoplasmosis
    °æÈ­È÷½ºÅäÇö󽺸¶Áõ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • giant cell carcinoma
    °Å¼¼Æ÷¾ÏÁ¾
  • glassy cell carcinoma of cervix
    À¯¸®¾ç ¼¼Æ÷ ÀڱðæºÎ¾Ï
  • granulosa cell carcinoma
    (³­¼Ò)°ú¸³¸·¼¼Æ÷ ¾ÏÁ¾(Õ°áµÎ¨í£Ø¯á¬øà ðþ).
  • BBT=£¾ basal body temperature
    ±âÃÊü¿Â.
  • BMR=£¾basal metabolic rate
    ±âÃÊ´ë»çÀ²
  • anterior basal branch
    ¾Õ¹Ù´Ú°¡Áö
  • anterior basal root
    ¾Õ¹Ù´ÚÁ¤¸Æ
  • anterior basal segment
    ¾Õ¹Ù´Ú±¸¿ª
  • anterior basal segmental bronchus
    ¾Õ¹Ù´Ú±¸¿ª±â°üÁö
  • inferior basal vein
    ¾Æ·¡¹Ù´ÚÁ¤¸Æ
  • plate, basal
    ±âÀúÆÇ (Æí¸ðÀÇ)
  • point of basal convergence
    ±âÃÊÆøÁÖÁ¡(Ðñõ¨ÜßñÍïÇ).
  • posterior basal branch
    µÚ¹Ù´Ú°¡Áö
  • posterior basal segment
    µÚ¹Ù´Ú±¸¿ª
  • posterior basal segmental bronchus
    µÚ¹Ù´Ú±¸¿ª±â°üÁö, ÈÄÆóÀúÁö(ý­øËî¼ò«).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • metastatic basal cell carcinoma
    ÀüÀ̼º±âÀú¼¼Æ÷¾Ï
  • morphea-like basal cell carcinoma
    ±¹¼Ò °æÇÇÁõ¾ç ±âÀú¼¼Æ÷¾Ï
  • nevoid basal cell carcinoma
    ¸ð¹Ý¾ç ±âÀú¼¼Æ÷¾Ï
  • nodulo-ulcerative basal cell carcinoma
    °áÀý ±Ë¾ç¼º ±âÀú¼¼Æ÷¾Ï
  • pigmented basal cell carcinoma
    »ö¼ÒÄ§Âø ±âÀú¼¼Æ÷¾Ï
  • rodent carcinoma => basal cell epithelioma
  • solid basal cell carcinoma
    °íÇü¼º ±âÀú¼¼Æ÷¾Ï
  • superficial basal cell carcinoma
    ¾èÀº ±âÀú¼¼Æ÷¾Ï
  • undifferentiated basal cell carcinoma
    ¹ÌºÐÈ­ ±âÀú¼¼Æ÷¾Ï
  • basal complex basal lamina
    ¹Ù´Úº¹ÇÕÃþ
  • basal nuclei basal ganglia
    ¹Ù´ÚÇÙ
  • lateral basal branch artery of basal trunk<³ª> ramus basalis lateralis (partis basalis)
    ¿ÜÃøÆóÀúµ¿¸Æ.
  • basal cell
    ¹Ù´Ú¼¼Æ÷
  • basal cell nevus
    ±âÀú¼¼Æ÷¸ð¹Ý
  • basal cell nevus syndrome
    ±âÀú¼¼Æ÷¸ð¹ÝÁõÈıº(¡­Ù½Úèñøý¦ÏØ).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Dark cell [Norepinephrine cell]
    ¾îµÎ¿î¼¼Æ÷ [³ë¸£¿¡Çdz×ÇÁ¸°¼¼Æ÷]
    [¿¾ ¿ë¾î] ¾Ï¼¼Æ÷(³ë¸£¿¡Çdz×ÇÁ¸°ºÐºñ¼¼Æ÷)
  • Chief cell [Type I glomus cell]
    °ú¸³¼¼Æ÷
    [¿¾ ¿ë¾î] ÁÖ¼¼Æ÷
  • Supporting cell [Sertoli cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁÖ¼¼Æ÷
  • Supporting cell [Type II glomus cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁö¼¼Æ÷
  • Supporting cell [Type II glomus cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁö¼¼Æ÷(Á¦2Çü»ç±¸¼¼Æ÷)
  • Lateral basal brach
    °¡Âʹٴڰ¡Áö
    [¿¾ ¿ë¾î] ¿ÜÃøÆóÀúµ¿¸Æ
  • Lateral basal branch
    °¡Âʹٴڰ¡Áö
    [¿¾ ¿ë¾î] ¿ÜÃøÆóÀúµ¿¸Æ
  • Lateral basal segment
    °¡Âʹٴڱ¸¿ª
    [¿¾ ¿ë¾î] ¿ÜÃøÆóÀú±¸
  • Lateral basal segmental bronchus
    °¡Âʹٴڱ¸¿ª±â°üÁö
    [¿¾ ¿ë¾î] ¿ÜÃøÆóÀúÁö
  • Basal plate
    ±âµÕ¹Ù´ÚÆÇ
    [¿¾ ¿ë¾î] °æÀúÆÇ
  • Basal vein
    ³ú¹Ù´ÚÁ¤¸Æ
    [¿¾ ¿ë¾î] ³úÀúÁ¤¸Æ
  • Basal part of cerebral peduncle
    ´ë³ú´Ù¸®¾ÕºÎºÐ
    [¿¾ ¿ë¾î] ´ë³ú°¢Àú
  • Posterior basal branch
    µÚ¹Ù´Ú°¡Áö
    [¿¾ ¿ë¾î] ÈÄÆóÀúµ¿¸Æ
  • Posterior basal segment
    µÚ¹Ù´Ú±¸¿ª
    [¿¾ ¿ë¾î] ÈÄÆóÀú±¸
  • Posterior basal segmental bronchus
    µÚ¹Ù´Ú±¸¿ª±â°üÁö
    [¿¾ ¿ë¾î] ÈÄÆóÀúÁö
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cell adhesion molecule
    ¼¼Æ÷ºÎÂøºÐÀÚ(á¬øàÜõó·ÝÂí­)
  • cell affinity
    ¼¼Æ÷ģȭ(á¬øàöÑûú)
  • cell blotting
    ¼¼Æ÷(á¬øà) ºí·ÔÆÃ
  • cell cloning
    ¼¼Æ÷(á¬øà) Ŭ·Î´×
  • cell coat
    ¼¼Æ÷(á¬øà)²®Áú
  • cell cycle
    ¼¼Æ÷ÁÖ±â(á¬øàñÎÑ¢)
  • cell differentiation
    ¼¼Æ÷ºÐÈ­(á¬øàÝÂûù)
  • cell envelope
    ¼¼Æ÷(á¬øà)½Î°³
  • cell factor
    ¼¼Æ÷ÀÎÀÚ(á¬øàì×í­)
  • cell fractionation
    ¼¼Æ÷ºÐȹȭ(á¬øàÝÂüñûù)
  • cell-free amino acid incorporating system
    ¹«¼¼Æ÷(Ùíá¬øà) ¾Æ¹Ì³ë»ê ÆíÀÔ(øºìý)¾¾½ºÅÛ
  • cell-free extract
    ¹«¼¼Æ÷ÃßÃâ¹°(Ùíá¬øàõÎõóÚª)
  • cell-free protein synthesis
    ¹«¼¼Æ÷´Ü¹éÁúÇÕ¼º(Ùíá¬øàÓ±ÛÜòõùêà÷)
  • cell-free system
    ¹«¼¼Æ÷(Ùíá¬øà)½Ã½ºÅÛ
  • cell fusion
    ¼¼Æ÷À¶ÇÕ(á¬øàë×ùê)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • adenoid cystic carcinoma
    ¼±¾ç³¶¼º¾ÏÁ¾
  • carcinoma
    ¾ÏÁ¾
  • carcinoma in situ
    »óÇdz»¾ÏÁ¾, µ¿¼Ò³»¾ÏÁ¾, ÀνÃÅõ¾ÏÁ¾
  • epidermoid carcinoma
    Ç¥ÇǾç¾ÏÁ¾
  • intraductal carcinoma
    °ü³»¾ÏÁ¾
  • invasive carcinoma
    ħ½À¼º¾ÏÁ¾
  • medullary carcinoma
    ¼öÁú¼º¾ÏÁ¾
  • mucinous carcinoma
    Á¡¾×¾ÏÁ¾
  • mucoepidermoid carcinoma
    Á¡¾×Ç¥ÇǾç¾ÏÁ¾
  • mucosal carcinoma
    Á¡¸·¾ÏÁ¾
  • pancreatic carcinoma
    ÃéÀå¾ÏÁ¾
  • undifferentiated carcinoma
    ¹ÌºÐÈ­¾ÏÁ¾
  • acinar cell
    Æ÷»ó¼¼Æ÷
  • air cell
    ÇԱ⵿
  • blast cell
    ¸ð¼¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
BCC Basal Cell Carcinoma
BCC basal-cell carcinoma; biliary cholesterol concentration; birth control clinic
MNBCCS multiple nevoid basal-cell carcinoma syndrome
NBCC nevoid basal cell carcinoma
NBCCS nevoid basal cell carcinoma syndrome
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
SSPE Subacute Sclerosing Panencephalitis
NSHD nodular sclerosing Hodgkin disease
SC sclerosing cholangitis
BCNS Basal Cell Nevus Syndrome
BCE Basal cell epithelioma
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • sclerosing osteogenic sarcoma
    °æÈ­¼º °ñ À°Á¾
  • sclerosing seratitis
    °æÈ­¼º °¢¸·¿°
  • basal cell
    ±âÀú ¼¼Æ÷, ±âÃÊ ¼¼Æ÷
    Ç¥ÇÇ ±âÀúÃþ¿¡ Á¸ÀçÇÏ´Â Ãʱâ ÄÉ¶óÆ¾ ¼¼Æ÷¸¦ ÀÏÄ´ À̸§. Æ÷À¯·ù Á¤¼ÒÀÇ ¼¼Á¤°ü ¼Ó¿¡¼­ ¿ÜÃø ±âÀú¸·¿¡ Á¢ÇÏ¿© »êÀçÇØ ÀÖ´Â ´ëÇü ¼¼Æ÷. ¼¼¸£Å縮 ¼¼Æ÷
  • basal cell adenocarainoma
    ±âÀú ¼¼Æ÷ ¼±¾Ï
    ¸Å¿ì µå¹°°í ±âÀú ¼¼Æ÷ ¼±Á¾ÀÇ ¾Ç¼ºÀÌ´Ù. ¿Ü°úÀû ÀýÁ¦ ½Ã ¿¹Èİ¡ ÁÁ´Ù.
  • basal cell epithelioma
    ±âÀú ¼¼Æ÷ »óÇÇ ¾Ï, ±âÀú ¼¼Æ÷ »óÇÇÁ¾
    Áß³â ÀÌÈÄ¿¡ »ý±â±â ½±°í ±× ŹÝÀÌ ¾È¸é ÇǺο¡ ¹ß»ýÇÑ´Ù. Ãø»öÀÇ ¼Ò°áÀýÀÌ Áý»êÇÑ Á¾¾çÀ» Çü¼ºÇϴµ¥ ¹Ý±¸»óÀ¸·Î À¶±âÇÏ´Â °Í, ÆíÆòÇÑ ¹Ý»óÀÇ ÆÛÁü µî ¿©·¯ °¡ÁöÀÌ´Ù. Á¶Á÷ÇÐÀûÀ¸·Î´Â ÇǺΠǥÇÇ ±âÀú ¼¼Æ÷ÀÇ Áõ½ÄÀÌ°í ¼¼Æ÷ ºÐ¿­, ÀÌÇü¼º µîÀº °ÅÀÇ ³ªÅ¸³ªÁö ¾Ê´Â´Ù.
  • basal cell hyperplasia
    ±âÀú ¼¼Æ÷ °úÇü¼º
  • basal cell nevus
    ±âÀú ¼¼Æ÷ ¸ð¹Ý
  • basal cell papilloma
    ±âÀú ¼¼Æ÷ À¯µÎÁ¾
  • basal-cell layer
    ±âÀú ¼¼Æ÷Ãþ
  • acinic cell carcinoma
    ¼±¹æ ¼¼Æ÷ ¾ÏÁ¾
    1. ¼±¹æ ¼¼Æ÷, ±Ù»óÇǼ¼Æ÷°¡ Áõ½ÄÇÏ¿© Çü¼ºµÇ°í ³·Àº ¾Ç¼ºµµ¸¦ º¸ÀδÙ. 2. Ÿ¾×¼± ¾à¼º Á¾¾ç Áß 5¹øÂ°ÀÇ ¹ß»ý ºñÀ²À» °®´Â Á¾¾çÀ¸·Î 90%¿¡¼­ ÀÌÇϼ±¿¡¼­ ¹ß»ýÇÏ¸ç ¾ÇÇϼ±°ú ¼ÒŸ¾×¼±¿¡¼­µµ µå¹°°Ô ¹ß»ýÇÑ´Ù. ¿©¼º¿¡¼­ ´Ù¼Ò È£¹ßÇϰí, ¾î´À ¿¬·É¿¡¼­³ª ¹ß»ýÇϳª ÁÖ·Î 30-70´ë¿¡ °ñ°í·ç ¹ß»ýÇÑ´Ù. ¿¹Àü¿¡´Â ¾ç¼ºÀ¸·Î »ý°¢ÇÏ¿© ¼±¹æ¼¼Æ÷Á¾À̶ó ºÎ¸¥ ÀûÀÌ ÀÖÀ¸³ª ºÐ¸íÇÑ ¾Ç¼ºÀ¸·Î ¼±¾ÏÁ¾À¸·Î ºÎ¸¥´Ù. Á¾¾ç ¼¼Æ÷´Â Àå¾×¼º ¼±¹æ¼¼Æ÷¿Í À¯»çÇÏÁö¸¸ ¿©·¯ °¡Áö ´Ù¸¥ ¼¼Æ÷µéÀÌ ³ªÅ¸³ª¸ç, °³Á¦°ü ¿¹ºñ¼¼Æ÷¿¡¼­ ±â¿øÇÑ´Ù°í º»´Ù.
  • adenosquamous cell carcinoma
    ¼± ÆíÆò»óÇÇ ¼¼Æ÷¾Ï
    ¼± ¾Ï°ú ÆíÆò¼¼Æ÷ ¾ÏÀÌ È¥ÀçµÇ¾î ÀÖ´Â °Í. ÀÚ±Ã°æ ³»¸· »óÇÇÀÇ ±âÀú Ãþ¿¡ ÀÖ´Â ¿¹ºñ ¼¼Æ÷¿¡¼­ ¹ß»ý. ÀÌ´Â °°Àº º´±âÀÇ ÆíÆò¼¼Æ÷ ¾Ï°ú ºñ±³ÇÏ¿© ¿¹Èİ¡ ´õ ³ª»Ú´Ù.
  • alveolar cell carcinoma
    ÆóÆ÷ ¼¼Æ÷ ¾ÏÁ¾
  • columnar cell carcinoma
    ¿øÁÖ ¼¼Æ÷ ¾ÏÁ¾
  • invasive squamous cell carcinoma
    ħÀÔ¼º ÆíÆò »óÇÇ ¼¼Æ÷ ¾Ï
  • non-keratinized squamous cell carcinoma
    ºñ°¢È­¼º ÆíÆò »óÇÇ ¼¼Æ÷ ¾Ï
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
chronic diffuse sclerosing osteomyelitis A proliferative reaction of bone to a low-grade infection of the jaws; most often seen in middle-aged or older black women as extensive, often bilateral radio-opacities of the mandible and maxilla.
(05 Mar 2000)
chronic focal sclerosing osteomyelitis A reaction of bone to a mild bacterial infection, often the result of a carious tooth, in persons with a high degree of tissue resistance; results in a localised radio-opacity.
Synonym: focal condensing osteitis.
(05 Mar 2000)
primary sclerosing cholangitis <radiology> Idiopathic, associated with IBD (50%), usually UC, M more than F, peak age 20-30 years of age, chronic inflammation and fibrosis of all bile ducts, stricture, obstruction, abscess (string of beads), intramural pseudo-diverticula, cholangiocarcinoma (10%!!), dilatation proximal to stricture may signal carcinoma Differential diagnosis: cholangiocarcinomarcinoma (diffuse form), primary biliary cirrhosis (PBC), AIDS-related cholangitis (? due to CMV)
(12 Dec 1998)
sclerosing adenosis A nodular, benign breast lesion occurring most frequently in relatively young women and consisting of hyperplastic distorted lobules of acinar tissue with increased collagenous stroma; the changes may be difficult to distinguish microscopically from carcinoma. Also, a benign nodular microscopic lesion of the prostate consisting of acimar tissue with increased stroma; the basal cell layer shows characteristic smooth muscle metaplasia.
Synonym: adenofibrosis, fibrosing adenomatosis, fibrosing adenosis.
(05 Mar 2000)
sclerosing agent A compound which acts by irritation of the veinous intimal epithelium; used in the treatment of varicose veins.
(05 Mar 2000)
sclerosing haemangioma <tumour> A benign lung or bronchial lesion, often subpleural, sometimes multiple, which forms hyalinised connective tissue.
Synonym: fibrous histiocytoma.
(05 Mar 2000)
sclerosing inflammation Inflammation leading to extensive formation of fibrous and scar tissue.
(05 Mar 2000)
sclerosing keratitis Inflammation of the cornea complicating scleritis; characterised by opacification of the corneal stroma.
(05 Mar 2000)
sclerosing leukoencephalitis <neurology> Chronic progressive illness seen in children a few years after measles infection and involving demyelination of the cerebral cortex. Virus apparently persists in brain cells: usually considered a slow virus disease.
(18 Nov 1997)
sclerosing mastoiditis A chronic mastoiditis in which the trabeculae are greatly thickened, almost or entirely obliterating the cells.
(05 Mar 2000)
sclerosing of varicose veins A procedure which involves the injection of a sclerosing agent (causes scarring) into varicose veins in the extremities. Sclerotherapy may also be performed in the oesophagus, using UGI endoscopy, in the treatment of oesophageal varices in patients with cirrhosis of the liver.
(27 Sep 1997)
sclerosing osteitis Fusiform thickening or increased density of bones, of unknown cause; it has been considered a form of chronic nonsuppurative osteomyelitis.
Synonym: condensing osteitis, Garre's disease.
Osteitis tuberculosa multiplex cystica, an osteitis of tuberculous origin, marked by numerous small cavities in the osseous substance.
Synonym: Jungling's disease.
(05 Mar 2000)
sclerosing solutions Chemical agents injected into veins to cause localised thrombosis and eventual fibrosis and obliteration of the vessels. They are used in the treatment of varicose veins, haemorrhoids, gastric and oesophageal varices, and peptic ulcer haemorrhage.
(12 Dec 1998)
sclerosing therapy A procedure which involves the injection of a sclerosing agent (causes scarring) into varicose veins in the extremities. Sclerotherapy may also be performed in the oesophagus, using UGI endoscopy, in the treatment of oesophageal varices in patients with cirrhosis of the liver.
(27 Sep 1997)
subacute sclerosing leukoencephalitis <neurology> Chronic progressive illness seen in children a few years after measles infection and involving demyelination of the cerebral cortex. Virus apparently persists in brain cells: usually considered a slow virus disease.
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cell sorter
    ¼¼Æ÷ ºÐº°±â
  • cell therapy
    ¼¼Æ÷¿ä¹ý(¾çÀÇ °«³­»õ³¢ÀÇ ¼¼Æ÷¸¦ ÁÖÀÔÇϴ ȸÃá¹ý ('
  • cell wall
    ¼¼Æ÷º®
  • cell-mediated immunity
    ¼¼Æ÷(¸Å°³)¼º ¸é¿ª(¼¼Æ÷¸·¿¡ ºÎÂøÇÏ´Â Ç×üÀÇ Á߻꿡 ÀÇÇÑ
  • closed-cell
    µ¶¸³±âÆ÷ÀÇ;¹ÐÆó±âÆ÷ÀÇ(¼ÒÀç´Â ÇÃ¶ó½ºÆ½µî)
  • complementary cell
    º¸Á· ¼¼Æ÷
  • condemned cell (ward)
    »çÇü¼ö °¨¹æ
  • corticopontine cell
    ÇÇÁú±³¼¼Æ÷(´ë³ú ÇÇÁú¿¡ ÀÖÀ¸¸ç ½Ã°¢ ÀÚ±ØÀ» ³ú±³¿¡ º¸³¿)
  • death cell
    »çÇü¼ö °¨¹æ(µ¶¹æ)
  • dry cell
    °ÇÀüÁö
  • egg cell
    ³­¼¼Æ÷;³­ÀÚ
  • fuel cell
    ¿¬·áÀüÁö
  • gangion cell
    ½Å°æÀý ¼¼Æ÷
  • gas cell
    ºñÇ༱ÀÇ °¡½º³¶ÀÇ ÇÑ ±¸È¹;°¡½ºÀüÁö
  • germ cell
    »ý½Ä ¼¼Æ÷
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á